What is the potential impact of integrating reduced-chemo and chemo-free approaches into ALL treatment strategies?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
What is the potential impact of integrating reduced-chemo and chemo-free approaches into ALL treatment strategies?
-
ナレーター：
-
著者：
The ALL Hub was pleased to speak with Elias Jabbour, MD Anderson Cancer Center, Houston, US. We asked, What is the potential impact of integrating reduced-chemotherapy and chemotherapy-free approaches into acute lymphoblastic leukemia (ALL) treatment strategies?
In this interview, Jabbour discusses the growing evidence supporting chemotherapy-reduced and chemotherapy-free treatment approaches in ALL. He highlights how advances in targeted therapies, including blinatumomab, inotuzumab ozogamicin, tyrosine kinase inhibitors, and CAR T-cell therapy, together with measurable residual disease-guided treatment strategies, are transforming the management of ALL. Drawing on recent clinical studies, he explores the potential to reduce chemotherapy intensity, minimize the need for allogeneic stem cell transplantation, and improve long-term outcomes across different ALL subtypes and patient populations.
This educational resource is independently supported by Amgen. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy for more information.